Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone

Elizabeth Sokol, Paul R. Haut, Yasmin Gosiengfiao, Kate Feinstein, Peter Pytel, Susan L. Cohn

Research output: Contribution to journalArticle


Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care.

Original languageEnglish (US)
Pages (from-to)512-514
Number of pages3
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Mar 1 2013



  • Neuroblastoma
  • Pathology
  • Refractory neuroblastoma
  • Relapsed neuroblastoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this